Cargando…

Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies

BACKGROUND: A vaccine is needed to control the spread of human immunodeficiency virus type 1 (HIV-1). An in vitro assay that can predict the protection induced by a vaccine would facilitate the development of such a vaccine. A potential candidate would be an assay to quantify neutralization of HIV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, David, Koornstra, Wim, Mortier, Daniella, Fagrouch, Zahra, Verschoor, Ernst J., Heeney, Jonathan L., Bogers, Willy M. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247218/
https://www.ncbi.nlm.nih.gov/pubmed/22216149
http://dx.doi.org/10.1371/journal.pone.0028974
_version_ 1782220058111508480
author Davis, David
Koornstra, Wim
Mortier, Daniella
Fagrouch, Zahra
Verschoor, Ernst J.
Heeney, Jonathan L.
Bogers, Willy M. J. M.
author_facet Davis, David
Koornstra, Wim
Mortier, Daniella
Fagrouch, Zahra
Verschoor, Ernst J.
Heeney, Jonathan L.
Bogers, Willy M. J. M.
author_sort Davis, David
collection PubMed
description BACKGROUND: A vaccine is needed to control the spread of human immunodeficiency virus type 1 (HIV-1). An in vitro assay that can predict the protection induced by a vaccine would facilitate the development of such a vaccine. A potential candidate would be an assay to quantify neutralization of HIV-1. METHODS AND FINDINGS: We have used sera from rhesus macaques that have been immunized with HIV candidate vaccines and subsequently challenged with simian human immunodeficiency virus (SHIV). We compared neutralization assays with different formats. In experiments with the standardized and validated TZMbl assay, neutralizing antibody titers against homologous SHIV(SF162P4) pseudovirus gave a variable correlation with reductions in plasma viremia levels. The target cells used in the assays are not just passive indicators of virus infection but are actively involved in the neutralization process. When replicating virus was used with GHOST cell assays, events during the absorption phase, as well as the incubation phase, determine the level of neutralization. Sera that are associated with protection have properties that are closest to the traditional concept of neutralization: the concentration of antibody present during the absorption phase has no effect on the inactivation rate. In GHOST assays, events during the absorption phase may inactivate a fixed number, rather than a proportion, of virus so that while complete neutralization can be obtained, it can only be found at low doses particularly with isolates that are relatively resistant to neutralization. CONCLUSIONS: Two scenarios have the potential to predict protection by neutralizing antibodies at concentrations that can be induced by vaccination: antibodies that have properties close to the traditional concept of neutralization may protect against a range of challenge doses of neutralization sensitive HIV isolates; a window of opportunity also exists for protection against isolates that are more resistant to neutralization but only at low challenge doses.
format Online
Article
Text
id pubmed-3247218
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32472182012-01-03 Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies Davis, David Koornstra, Wim Mortier, Daniella Fagrouch, Zahra Verschoor, Ernst J. Heeney, Jonathan L. Bogers, Willy M. J. M. PLoS One Research Article BACKGROUND: A vaccine is needed to control the spread of human immunodeficiency virus type 1 (HIV-1). An in vitro assay that can predict the protection induced by a vaccine would facilitate the development of such a vaccine. A potential candidate would be an assay to quantify neutralization of HIV-1. METHODS AND FINDINGS: We have used sera from rhesus macaques that have been immunized with HIV candidate vaccines and subsequently challenged with simian human immunodeficiency virus (SHIV). We compared neutralization assays with different formats. In experiments with the standardized and validated TZMbl assay, neutralizing antibody titers against homologous SHIV(SF162P4) pseudovirus gave a variable correlation with reductions in plasma viremia levels. The target cells used in the assays are not just passive indicators of virus infection but are actively involved in the neutralization process. When replicating virus was used with GHOST cell assays, events during the absorption phase, as well as the incubation phase, determine the level of neutralization. Sera that are associated with protection have properties that are closest to the traditional concept of neutralization: the concentration of antibody present during the absorption phase has no effect on the inactivation rate. In GHOST assays, events during the absorption phase may inactivate a fixed number, rather than a proportion, of virus so that while complete neutralization can be obtained, it can only be found at low doses particularly with isolates that are relatively resistant to neutralization. CONCLUSIONS: Two scenarios have the potential to predict protection by neutralizing antibodies at concentrations that can be induced by vaccination: antibodies that have properties close to the traditional concept of neutralization may protect against a range of challenge doses of neutralization sensitive HIV isolates; a window of opportunity also exists for protection against isolates that are more resistant to neutralization but only at low challenge doses. Public Library of Science 2011-12-28 /pmc/articles/PMC3247218/ /pubmed/22216149 http://dx.doi.org/10.1371/journal.pone.0028974 Text en Davis et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Davis, David
Koornstra, Wim
Mortier, Daniella
Fagrouch, Zahra
Verschoor, Ernst J.
Heeney, Jonathan L.
Bogers, Willy M. J. M.
Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title_full Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title_fullStr Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title_full_unstemmed Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title_short Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
title_sort protection in macaques immunized with hiv-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247218/
https://www.ncbi.nlm.nih.gov/pubmed/22216149
http://dx.doi.org/10.1371/journal.pone.0028974
work_keys_str_mv AT davisdavid protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT koornstrawim protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT mortierdaniella protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT fagrouchzahra protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT verschoorernstj protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT heeneyjonathanl protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies
AT bogerswillymjm protectioninmacaquesimmunizedwithhiv1candidatevaccinescanbepredictedusingthekineticsoftheirneutralizingantibodies